Ovarian Cancer

An oncologist explains the importance of molecular testing in ovarian cancer and the implications of testing on treatment selection.

Lyndsay Willmott, MD, presents the case of a 57-year-old woman with ovarian cancer.

In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.

John Diaz, MD, discusses the current results of the phase 1 trial of STRO-002, a novel FRα-targeting antibody-drug conjugate, in patients with ovarian cancer.

In an interview with Targeted Oncology, John Diaz, MD, discussed the ovarian cancer treatment paradigm and the promise of STRO-002 for an important ovarian cancer subgroup.

Ramez Eskander, MD, summarizes the current status of ovarian cancer treatment and reviews unanswered questions and future directions.

Dr Ramez Eskander shares his insights on considerations for selecting appropriate PARP inhibitor therapy for patients based on molecular testing and other factors.

An expert in ovarian cancer discusses the mechanism of action of PARP inhibitors in treating advanced ovarian cancer and comments on tolerability profiles of available agents.

Ramez Eskander, MD, describes the ARIEL3 study of rucaparib switch maintenance therapy in patients with advanced ovarian cancer.

Dr Ramez Eskander reviews the options and goals for frontline maintenance therapy in women with advanced ovarian cancer.

An expert in ovarian cancer reviews best practices for molecular testing in patients with advanced ovarian cancer and the implications of testing results for treatment selections.

Ramez Eskander, MD, discusses the case of a 64-year-old woman diagnosed with ovarian cancer.

In an interview with Targeted Oncology, Rodney P. Rocconi, MD, FACOG, discussed the analysis of the homologous recombination proficient patients with advanced-stage ovarian cancer treated in the phase 2 VITAL study as well as a biomarker analysis.

Two international studies of oregovomab in combination with other anticancer therapies for the treatment of previously treated, recurrent ovarian cancer have dose its first patients, and patients are being recruited to receive the drug in a phase 3 study conducted in the United States.

Gizelka David-West, MD, analyzes the most compelling changes in up-front treatment and maintenance therapy for Ovarian Cancer Awareness Month.

In an interview with Targeted Oncology™, Stephanie L. Wethington, MD, MSc, discussed the modern treatment of high-grade serous ovarian cancer and the study of olaparib plus ceralasertib as a strategy for overcoming resistance to PARP inhibition.

The FDA has granted a fast track designation to the folate receptor alpha-targeting antibody-drug conjugate, STRO-002, for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.

In an interview with Targeted Oncology™, David O’Malley, MD, discussed the results from an arm of the phase 2 study of 5 mirvetuximab-containing regimens that were evaluated for the treatment of patients with FRα-positive ovarian cancer.

Outcomes in patients with advanced recurrent ovarian cancer treated with the novel immunotherapeutic vaccine maveropepimut-S appeared encouraging, according to topline results from the DeCidE1 clinical trial.

In an interview with Targeted Oncology™ following a presentation of the study protocol at the 2021 American Society of Clinical Oncology Annual Meeting, Susana K. Banerjee, PhD, explained the progress of ENGOT-ov60/GOG3052/RAMP 201 in detail.

In an interview with Targeted Oncology, Ainhoa Madariaga, MD, explained the similarities between the primary and exploratory analyses of adavosertib and gemcitabine in patients with ovarian cancer as it relates to toxicity.

In an interview with Targeted Oncology, Rachel N. Grisham, MD, discussed binimetinib’s effect on patients with ovarian cancer harboring a KRAS mutation. 

In an interview with Targeted Oncology, Kathleen Moore, MD, discusses the effects of niraparib for ovarian cancer in the earlier-line setting in more detail and how she anticipates it will change clinical practice. 

In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.